| scholarly article | Q13442814 |
| P356 | DOI | 10.1056/NEJMC052939 |
| P698 | PubMed publication ID | 16760459 |
| P50 | author | Julio Montaner | Q1712378 |
| Mark W. Tyndall | Q51002222 | ||
| Thomas Kerr | Q85344273 | ||
| Evan Wood | Q85344858 | ||
| Calvin K Lai | Q87993281 | ||
| Ruth Zhang | Q114738775 | ||
| P2093 | author name string | Jo-Anne Stoltz | |
| P433 | issue | 23 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 2512-2514 | |
| P577 | publication date | 2006-06-01 | |
| P1433 | published in | The New England Journal of Medicine | Q582728 |
| P1476 | title | Attendance at supervised injecting facilities and use of detoxification services | |
| P478 | volume | 354 |
| Q92635789 | "Beyond Safer Injecting"-Health and Social Needs and Acceptance of Support among Clients of a Supervised Injecting Facility |
| Q38214383 | A Canadian perspective on addiction treatment |
| Q41993740 | A historical review of HIV prevention and care initiatives in British Columbia, Canada: 1996-2015 |
| Q39947017 | A peer-led mobile outreach program and increased utilization of detoxification and residential drug treatment among female sex workers who use drugs in a Canadian setting |
| Q33910606 | Acceptability and design preferences of supervised injection services among people who inject drugs in a mid-sized Canadian City |
| Q34221599 | An appeal to humanity: legal victory in favour of North America's only supervised injection facility: Insite |
| Q34115061 | Are young injection drug users ready and willing to participate in preventive HCV vaccine trials? |
| Q57690350 | Burden of HIV infection among aboriginal injection drug users in Vancouver, British Columbia |
| Q36380319 | Canada's highest court unchains injection drug users; implications for harm reduction as standard of healthcare |
| Q40351462 | Commentary on Enns et al. (2016): Supervised injection facilities as a cost-effective intervention |
| Q36453781 | Controlling illegal stimulants: a regulated market model |
| Q37377762 | DETERMINANTS OF CUTANEOUS INJECTION-RELATED INFECTIONS AMONG INJECTION DRUG USERS AT AN EMERGENCY DEPARTMENT. |
| Q38024744 | Deadly public policy: what the future could hold for the HIV epidemic among injection drug users in Vancouver |
| Q45173357 | Dermatologic manifestations of underlying infectious disease among illicit injection-drug users |
| Q33599370 | Determinants of hospitalization for a cutaneous injection-related infection among injection drug users: a cohort study |
| Q57153779 | Developing Canada's research base for harm reduction and health equity approaches to HIV prevention and treatment |
| Q37973813 | Drug policy and the public good: evidence for effective interventions |
| Q37638349 | Drug use in business bathrooms: An exploratory study of manager encounters in New York City |
| Q90592568 | Elimination of HIV transmission through novel and established prevention strategies among people who inject drugs |
| Q28473764 | Estimated drug overdose deaths averted by North America's first medically-supervised safer injection facility |
| Q58755682 | Evaluation of a fentanyl drug checking service for clients of a supervised injection facility, Vancouver, Canada |
| Q41193164 | Examining the potential role of a supervised injection facility in Saskatoon, Saskatchewan, to avert HIV among people who inject drugs. |
| Q89451350 | Expanding supervised injection facilities across Canada: lessons from the Vancouver experience |
| Q57690504 | Factors Associated with Public Injecting Among Users of Vancouver's Supervised Injection Facility |
| Q37032437 | Fighting addiction's death row: British Columbia Supreme Court Justice Ian Pitfield shows a measure of legal courage |
| Q28244216 | HIV prevention in clinical care settings: 2014 recommendations of the International Antiviral Society-USA Panel |
| Q39959718 | Harm reduction in hospitals: is it time? |
| Q42676669 | IDU Perspectives on the Design and Operation of North America's First Medically Supervised Injection Facility |
| Q52292576 | Illicit drug addiction, infectious disease spread, and the need for an evidence-based response. |
| Q64117950 | Impact of drug consumption rooms on risk practices and access to care in people who inject drugs in France: the COSINUS prospective cohort study protocol |
| Q35127554 | Inability to access addiction treatment and risk of HIV infection among injection drug users recruited from a supervised injection facility. |
| Q41502073 | Injection drug use cessation and use of North America's first medically supervised safer injecting facility |
| Q47316128 | Injection drug users' access to a supervised injection facility in Vancouver, Canada: the influence of operating policies and local drug culture |
| Q43132332 | Insite: Canada's landmark safe injecting program at risk |
| Q99710074 | Integrating harm reduction and clinical care: Lessons from Covid-19 respite and recuperation facilities |
| Q89203281 | Nontraditional Alcohol and Opioid Agonist Treatment Interventions |
| Q92682557 | Opioid agonist treatment and the process of injection drug use initiation |
| Q57803159 | Perspectives on supervised injection facilities among service industry employees in New York City: A qualitative exploration |
| Q24649575 | Police and public health partnerships: evidence from the evaluation of Vancouver's supervised injection facility |
| Q64113306 | Potential use of supervised injection services among people who inject drugs in a remote and mid-size Canadian setting |
| Q46696473 | Preventing HIV and Hepatitis Infections Among People Who Inject Drugs: Leveraging an Indiana Outbreak Response to Break the Impasse |
| Q50217902 | Public Health and Public Order Outcomes Associated with Supervised Drug Consumption Facilities: a Systematic Review |
| Q34178819 | Reduction in overdose mortality after the opening of North America's first medically supervised safer injecting facility: a retrospective population-based study. |
| Q36041992 | Risky and rushed public crack cocaine smoking: the potential for supervised inhalation facilities |
| Q33572831 | Science and ideology |
| Q24673390 | Summary of findings from the evaluation of a pilot medically supervised safer injecting facility |
| Q30234420 | Supervised injection facilities in Canada: past, present, and future |
| Q90568818 | Supervised injection facility use and exposure to violence among a cohort of people who inject drugs: A gender-based analysis |
| Q37229662 | Supervised injection sites: prejudice should not trump evidence of benefit |
| Q34582040 | The impact of drug use patterns on mortality among polysubstance users in a Canadian setting: a prospective cohort study |
| Q24657290 | The law (and politics) of safe injection facilities in the United States |
| Q34764625 | The role of safer injection facilities in the response to HIV/AIDS among injection drug users. |
| Q37074324 | The syringe gap: an assessment of sterile syringe need and acquisition among syringe exchange program participants in New York City |
| Q34781762 | Toward a comprehensive approach to HIV prevention for people who use drugs |
| Q33488345 | Unstable housing and hepatitis C incidence among injection drug users in a Canadian setting |
| Q34403782 | Use of a medically supervised injection facility among street youth |
| Q45069794 | Use of on-site detoxification services co-located with a supervised injection facility |
| Q89432302 | Use of withdrawal management services among people who use illicit drugs in Vancouver, Canada |
| Q36952768 | Vaccine immunogenicity in injecting drug users: a systematic review |
| Q34142633 | Vancouver's supervised injection facility challenges Canada's drug laws |
Search more.